Biological response modifiers: realizing their potential in cancer therapeutics

James E. Talmadge

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The therapeutic activity of biological response modifiers has only recently been observed in cancer patients although some have in fact been in use for the past 35 years. Several cloned immunoregulatory agents such as the interleukins and bacterial adjuvants such as BCG have apparently shown disappointing therapeutic activity in the clinic but James Talmadge explains that the design of Phase I trials may yield insufficient information to assess accurately the immunomodulatory and clinical effects of potentially useful biological response modifiers.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalTrends in Pharmacological Sciences
Issue numberC
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Biological response modifiers: realizing their potential in cancer therapeutics'. Together they form a unique fingerprint.

Cite this